Chardan Capital Maintains Buy on Palvella Therapeutics, Raises Price Target to $240

Benzinga Newsdesk www.benzinga.com Positive 88.6%

Neg 0% Neu 0% Pos 88.6%

Chardan Capital analyst Geulah Livshits maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and raises the price target from $210 to $240.